This article was originally posted by CNBC.com
Kari Firestone’s newest article discusses why the incentives for companies and research organizations may not be aligned with customers’ desire for lower drug prices. Additionally, the legal complexity of the Medicare system leaves the government with no negotiating power, further inflating prescription drug prices.
